Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated different centrifugation systems and found that low-speed protocols and certified centrifuges produced better-quality platelet-rich fibrin and recommended using FDA-approved glass tubes for safe and effective regenerative outcomes.

This review highlights preclinical and clinical advancements in gene and cell therapies for epidermolysis bullosa and ichthyosis, noting a recently FDA-approved gene therapy for recessive dystrophic EB.

This article discusses hormonal mechanisms underlying androgenetic alopecia but does not report any new findings; it reviews the roles of dihydrotestosterone and available FDA-approved treatments.

In this study, the researchers performed a comparative analysis of drug-target interaction data from multiple databases to refine drug repurposing strategies, revealing potential associations between drug characteristics and therapeutic groups, and predicting repositioning opportunities for FDA-approved drugs across major cancer types.

This literature review highlights varying recommendations for testosterone use in peri- and postmenopausal women, noting its accepted role in treating hypoactive sexual desire disorder but stressing controversy and lack of FDA-approved options for broader use.

This article reviews the use of several medications for ovulation induction in polycystic ovary syndrome and hirsutism treatment, noting these uses are not FDA-approved; no new clinical results are provided.

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.

This study found that DKK1-targeting siRNA, which may activate the Wnt/β-catenin signaling pathway, showed hair growth results in mice similar to those treated with the FDA-approved minoxidil, suggesting potential as an androgenetic alopecia therapy.

This source highlights concerns about the safety and efficacy of dietary supplements marketed for hair loss, citing a lack of FDA testing and potential risks such as adverse side effects, interference with medical tests, and withholding of ingredient information.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but it presents no new research findings.

This source highlights that the incidence of alopecia areata is increasing among children, and while corticosteroids and Janus kinase inhibitors show potential effectiveness and safety, they remain unapproved by the FDA for pediatric use.

In this study, exosomes were identified as influential in skin biology, demonstrating potential in accelerating wound healing by modulating inflammation and enhancing tissue regeneration, though their use remains primarily cosmetic pending FDA approval.

This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.

This review discusses the epidemiology, pathophysiology, diagnosis, and management of male androgenetic alopecia, noting that combination treatments, including FDA-approved and emerging therapies, may improve outcomes without added side effects.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This article discusses the management of pediatric alopecia areata in children aged 6 to 11, emphasizing the need for psychosocial support and limited medical treatments, as no systemic therapies are FDA-approved for this age group, despite the significant psychosocial burden.

This study explored recent advancements in hair restoration, particularly focusing on plant-derived exosomes and biomimetic polypeptides, which enhance hair follicle regeneration and growth, offering a promising alternative to human or animal-derived exosomes subject to FDA restrictions.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.

This paper reviews the current evidence regarding the off-label use of spironolactone for acne management, noting that despite its long-standing application in acne treatment, it has not yet received FDA approval for this indication.

This article highlights that trichorrhexis nodosa, a common type of hair breakage, is influenced by factors like heat styling and chemical treatments, with potential FDA action on formaldehyde usage in hair products potentially altering its treatment approach.

In this research, preclinical and early clinical studies on exosomes indicate their potential to modulate wound healing, skin rejuvenation, and hair growth in facial plastic surgery, but these treatments remain experimental until receiving FDA approval and robust clinical validation.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study reviews the use of lasers and light therapies as treatment options for managing the two most common types of alopecia—androegenetic alopecia and alopecia areata—highlighting that existing FDA-approved drugs like minoxidil and finasteride are partially effective, necessitating additional therapeutic approaches.

In this discussion of lavender products, the authors highlighted their traditional use for therapeutic purposes, aromatic qualities, and skincare applications, though lavender's medical efficacy remains unsupported by FDA approval and its primary mechanisms of action are not yet fully understood.

In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.